Skip to main content
Roger Waltzman, MD, Oncology, Jersey City, NJ

Roger J Waltzman MD MBA

Oncology•Jersey City, NJ

Hematologic Oncology, Complementary and Integrative

Chief Medical Officer, Molecular Templates

Join to View Full Profile

  • Molecular Templates185 Hudson Street, Suite 1510Jersey City, NJ 07311

  • Phone+1 862-204-4860

Dr. Waltzman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Waltzman's Full ProfileAlready have an account?

Education & Training

  • Columbia Business School
    Columbia Business SchoolMBA, Business, 2004 - 2006
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
  • The Warren Alpert Medical School of Brown University
    The Warren Alpert Medical School of Brown UniversityClass of 1992

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1998 - 2026
  • NY State Medical License
    NY State Medical License 1995 - 2026
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) ...
    Roger Waltzman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • MT-5111: A novel HER2 targeting engineered toxin body in clinical development. 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020

Press Mentions

  • EPS for Molecular Templates, Inc. (MTEM) Expected at $0.16
    EPS for Molecular Templates, Inc. (MTEM) Expected at $0.16March 7th, 2019
  • Rgenix Treats First Patient in Phase 1 Trial of RGX-202
    Rgenix Treats First Patient in Phase 1 Trial of RGX-202October 31st, 2018
  • Rgenix Bags $40M to Advance Cancer Drugs, Including GSK Castoff
    Rgenix Bags $40M to Advance Cancer Drugs, Including GSK CastoffOctober 9th, 2018
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Roger Waltzman, Dr. Roger Waltzman, MD, Dr. R Waltzman, Dr. Roger J Waltzman